Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have a product program in earlier development that features a unique mechanism of action with potential in chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578
Hans@LifeSciAdvisors.com

Recent News

3Oct

CymaBay Therapeutics Announces Three Presentations at The Liver MeetingĀ® 2022

14Sep

CymaBay Therapeutics Hosting Virtual Analyst Day on September 22

6Sep

CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Upcoming Event

Nov 4 2022

The Liver MeetingĀ® 2022

November 4 - November 8, 2022

Washington, DC

Q2 2022 Quarterly Results